Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer

Annals of Surgical Oncology

Volumn 18, Issue 4, 2011, Pages 1122-1129

  Bao, Philip Q ^a   Ramanathan, Ramesh K ^b   Krasinkas, Alyssa ^c   Bahary, Nathan ^c   Lembersky, Barry C ^c   Bartlett, David L ^c   Hughes, Steven J ^c   Lee, Kenneth K ^c   Moser, A James ^c   Zeh III, Herbert J ^c  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b Virginia G Piper Cancer Center   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLEEDING; CANCER RECURRENCE; CANCER SURGERY; CELLULITIS; CLINICAL ARTICLE; DEHYDRATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFECTION; MALE; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; SKIN DISEASE; WEAKNESS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PANCREATECTOMY; PANCREATIC NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79955873823     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1401-9     Document Type: Article

References (28)

1. Van den Broeck A, Sergeant G, Ectors N, et al. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2009;35:600-4.
2. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10:1199-210.
3. Neoptolemos JP, Buchler MW, Stocken DD, et al. ESPAC-3(v2): a multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol. 2009;27(Suppl):LBA4505.
4. Neoptolemos JP, Stocken DD, Tudur Smith C, et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer. 2009;100:246-50.
5. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-10. (Pubitemid 38339364)
6. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999; 230:776-82.
7. Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908-15.
8. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299:1019-26. (Pubitemid 351347058)
9. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-77. (Pubitemid 46143304)
10. Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003;21:3402-8. (Pubitemid 46594072)
11. Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:3778-85.
12. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19:3159-67. (Pubitemid 30428195)
13. Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res. 2003;284:122-30. (Pubitemid 36331971)
14. Fjallskog ML, Lejonklou MH, Oberg KE, et al. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.Clin CancerRes. 2003;9:1469-73. (Pubitemid 36418403)
15. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-6. (Pubitemid 46972777)
16. Dacic S, Shuai Y, Yousem S, et al. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol. 2010;23:159-68.
17. Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234: 758-68. (Pubitemid 33117196)
18. Linehan DC, Tan MC, Strasberg SM, et al. Adjuvant interferonbased chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study. Ann Surg. 2008;248:145-51.
19. Boeck S, Vehling-Kaiser U, Waldschmidt D, et al. Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, crossover phase III trial of the " Arbeitsgemeinschaft Internistische Onkologie." Anticancer Drugs. 2010;21:94-100.
20. Xiong HQ, Abbruzzese JL. Epidermal growth factor receptortargeted therapy for pancreatic cancer. Semin Oncol. 2002;29: 31-7. (Pubitemid 35191044)
21. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer- molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133-44. (Pubitemid 41058345)
22. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008;26:4268-75.
23. Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2010;28:744-52.
24. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res. 2007;13:2890-6. (Pubitemid 46849563)
25. Sun JF, Wu RR, Norris C, et al. Safety of chronic low-dose capecitabine as maintenance therapy in gastrointestinal cancers. Gastrointest Cancer Res. 2009;3:134-40.
26. Campbell F, Smith RA, Whelan P, et al. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology. 2009;55:277-83.
27. Raut CP, Tseng JF, Sun CC, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007;246:52-60. (Pubitemid 47012207)
28. Bao P, Potter D, Eisenber DP, et al. Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma. HPB (Oxford). 2009;11:606-11.